| 摘要 |
<p><P>PROBLEM TO BE SOLVED: To provide a new cancer treating agent containing an antibody against a cancer-specific membrane antigen that is effective for an invalid example of the trastuzumab. <P>SOLUTION: The cancer treating agent comprises an antibody that exhibits antibody-dependent cytotoxic activity to a cancer-specific membrane antigen expressed in an epithelial cancer cell, where the cancer treating agent is used for a living body with an epithelial cancer where the cancer-specific membrane antigen is positive and the ligand to KLRG1 (Killer cell Lectin-like Receptor G1) is positive, and where the initiation time of administration of the cancer treating agent is during or after practice of leukocyte-removing therapy where the blood of the living body is extracorporeally circulated to remove leukocytes from the blood. <P>COPYRIGHT: (C)2012,JPO&INPIT</p> |
